Astrazeneca Pharma
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
AstraZeneca Pharma India received permission from the Central Drugs Standard Control Organization on August 7 to import, sell and distribute Enhertu for an additional indication in India. The indication covered adults with HER2-positive breast cancer who had residual invasive disease after neoadjuvant trastuzumab, with or without pertuzumab, and taxane-based treatment. The company had received a separate permission for another Enhertu label expansion on July 28, 2026, and had recorded 12 regulatory approvals by that month. Oncology products accounted for 74.7% of FY26 sales, while revenue rose 33% to ₹22,756 million.
Powered by Tijori
AstraZeneca Pharma India received permission from the Central Drugs Standard Control Organization on August 7 to import, sell and distribute Enhertu for an additional indication in India. The indication covered adults with HER2-positive breast cancer who had residual invasive disease after neoadjuvant trastuzumab, with or without pertuzumab, and taxane-based treatment. The company had received a separate permission for another Enhertu label expansion on July 28, 2026, and had recorded 12 regulatory approvals by that month. Oncology products accounted for 74.7% of FY26 sales, while revenue rose 33% to ₹22,756 million.
Powered by Tijori
AstraZeneca Pharma India received permission from India’s drug regulator to import and sell Enhertu (trastuzumab deruxtecan) for an additional indication covering neoadjuvant treatment of HER2-positive Stage II or III breast cancer. Enhertu is one of three oncology products that have driven the company’s revenue growth in recent years. In the year to March 2026, revenue rose 33% to ₹22,756 million, with oncology contributing roughly 75% of product sales. The company secured 11 regulatory approvals in FY26 and operated debt-free with net cash of ₹4.5 billion.
Powered by Tijori
AstraZeneca Pharma India received permission from India’s drug regulator to import and sell Enhertu (trastuzumab deruxtecan) for an additional indication covering neoadjuvant treatment of HER2-positive Stage II or III breast cancer. Enhertu is one of three oncology products that have driven the company’s revenue growth in recent years. In the year to March 2026, revenue rose 33% to ₹22,756 million, with oncology contributing roughly 75% of product sales. The company secured 11 regulatory approvals in FY26 and operated debt-free with net cash of ₹4.5 billion.
Powered by Tijori
July 28 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA PHARMA INDIA - RECEIVES PERMISSION TO IMPORT AND SELL TRASTUZUMAB DERUXTECAN FOR ADDITIONAL INDICATION
Source text: ID:nBSE744v9g
Further company coverage: ASTR.NS
(([email protected];;))
July 28 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA PHARMA INDIA - RECEIVES PERMISSION TO IMPORT AND SELL TRASTUZUMAB DERUXTECAN FOR ADDITIONAL INDICATION
Source text: ID:nBSE744v9g
Further company coverage: ASTR.NS
(([email protected];;))
July 21 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA PHARMA INDIA - BHAVANA AGRAWAL RESIGNS AS CFO EFFECTIVE AUGUST 31, 2026
Source text: ID:nBSEbZMPhT
Further company coverage: ASTR.NS
(([email protected];))
July 21 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA PHARMA INDIA - BHAVANA AGRAWAL RESIGNS AS CFO EFFECTIVE AUGUST 31, 2026
Source text: ID:nBSEbZMPhT
Further company coverage: ASTR.NS
(([email protected];))
AstraZeneca Pharma India obtained permission from the Central Drugs Standard Control Organisation to import and market Benralizumab, branded as Fasenra, for an additional indication — Hypereosinophilic Syndrome (HES) in patients aged 12 years and older without an identifiable non-haematologic secondary cause. The July 15, 2026 approval covers the 30 mg/ml solution for injection in a pre-filled syringe. The drug, which depletes eosinophils, is already used globally for severe eosinophilic asthma; the new indication targets a rare disorder characterised by elevated eosinophil counts. AstraZeneca stated that the permission enables the launch of Fasenra for HES in India, subject to related statutory approvals.
Powered by Tijori
AstraZeneca Pharma India obtained permission from the Central Drugs Standard Control Organisation to import and market Benralizumab, branded as Fasenra, for an additional indication — Hypereosinophilic Syndrome (HES) in patients aged 12 years and older without an identifiable non-haematologic secondary cause. The July 15, 2026 approval covers the 30 mg/ml solution for injection in a pre-filled syringe. The drug, which depletes eosinophils, is already used globally for severe eosinophilic asthma; the new indication targets a rare disorder characterised by elevated eosinophil counts. AstraZeneca stated that the permission enables the launch of Fasenra for HES in India, subject to related statutory approvals.
Powered by Tijori
July 16 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA PHARMA INDIA - RECEIVES PERMISSION TO IMPORT AND SELL BENRALIZUMAB (FASENRA) FOR ADDITIONAL INDICATION
Source text: ID:nNSE406Jqs
Further company coverage: ASTR.NS
(([email protected];;))
July 16 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA PHARMA INDIA - RECEIVES PERMISSION TO IMPORT AND SELL BENRALIZUMAB (FASENRA) FOR ADDITIONAL INDICATION
Source text: ID:nNSE406Jqs
Further company coverage: ASTR.NS
(([email protected];;))
AstraZeneca Pharma India received permission from India's drug regulator to import and market its antibody-drug conjugate Trastuzumab deruxtecan, sold as Enhertu, for a new indication: first-line treatment of unresectable or metastatic HER2-positive breast cancer in adults, in combination with pertuzumab. The approval from the Central Drugs Standard Control Organization expands the drug's eligible patient pool in India beyond any previously cleared indications. Enhertu is a globally established therapy that generated over $3 billion in sales worldwide in the last financial year. The company said the permission paves the way for marketing the drug for the specified indication, subject to any related statutory approvals.
Powered by Tijori
AstraZeneca Pharma India received permission from India's drug regulator to import and market its antibody-drug conjugate Trastuzumab deruxtecan, sold as Enhertu, for a new indication: first-line treatment of unresectable or metastatic HER2-positive breast cancer in adults, in combination with pertuzumab. The approval from the Central Drugs Standard Control Organization expands the drug's eligible patient pool in India beyond any previously cleared indications. Enhertu is a globally established therapy that generated over $3 billion in sales worldwide in the last financial year. The company said the permission paves the way for marketing the drug for the specified indication, subject to any related statutory approvals.
Powered by Tijori
June 11 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA PHARMA - RECEIVED PERMISSION TO IMPORT FOR SALE OF TRASTUZUMAB DERUXTECAN
Source text: ID:nBSE6vFWJS
Further company coverage: ASTR.NS
(([email protected];))
June 11 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA PHARMA - RECEIVED PERMISSION TO IMPORT FOR SALE OF TRASTUZUMAB DERUXTECAN
Source text: ID:nBSE6vFWJS
Further company coverage: ASTR.NS
(([email protected];))
** Biopharma company Astrazeneca Pharma India's shares ASTR.NS fall as much as 6.76% to 8,357 rupees apiece
** This is stock's steepest intraday decline in two months
** ASTR posts a 23% year-on-year drop in March quarter profit; operating profit slips 29.5%
** Stock is most active in six weeks, with a trading volume of 35,516 shares as of 12:17 p.m. IST, more than quadruple the 30-day average volume, data compiled by LSEG shows
** ASTR shares are down 5.8% in 2026 so far, according to exchange data
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463;))
** Biopharma company Astrazeneca Pharma India's shares ASTR.NS fall as much as 6.76% to 8,357 rupees apiece
** This is stock's steepest intraday decline in two months
** ASTR posts a 23% year-on-year drop in March quarter profit; operating profit slips 29.5%
** Stock is most active in six weeks, with a trading volume of 35,516 shares as of 12:17 p.m. IST, more than quadruple the 30-day average volume, data compiled by LSEG shows
** ASTR shares are down 5.8% in 2026 so far, according to exchange data
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463;))
May 26 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA PHARMA INDIA LTD - RECOMMENDS DIVIDEND OF 36 RUPEES PER EQUITY SHARE FOR FY2025-26
Source text: ID:nBSEbBnmHB
Further company coverage: ASTR.NS
(([email protected];))
May 26 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA PHARMA INDIA LTD - RECOMMENDS DIVIDEND OF 36 RUPEES PER EQUITY SHARE FOR FY2025-26
Source text: ID:nBSEbBnmHB
Further company coverage: ASTR.NS
(([email protected];))
March 17 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
RECEIVES PERMISSION TO IMPORT DURVALUMAB (IMFINZI) FOR ADDITIONAL INDICATION
Source text: ID:nBSE4YQpNZ
Further company coverage: ASTR.NS
(([email protected];;))
March 17 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
RECEIVES PERMISSION TO IMPORT DURVALUMAB (IMFINZI) FOR ADDITIONAL INDICATION
Source text: ID:nBSE4YQpNZ
Further company coverage: ASTR.NS
(([email protected];;))
Feb 11 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA PHARMA INDIA DEC-QUARTER PAT 325.9 MILLION RUPEES
ASTRAZENECA PHARMA INDIA DEC-QUARTER REVENUE FROM OPERATIONS 6.12 BILLION RUPEES
Source text: ID:nBSE5MKvG0
Further company coverage: ASTR.NS
(([email protected];))
Feb 11 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA PHARMA INDIA DEC-QUARTER PAT 325.9 MILLION RUPEES
ASTRAZENECA PHARMA INDIA DEC-QUARTER REVENUE FROM OPERATIONS 6.12 BILLION RUPEES
Source text: ID:nBSE5MKvG0
Further company coverage: ASTR.NS
(([email protected];))
Feb 10 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA PHARMA INDIA LTD - RECEIVES PERMISSION TO IMPORT DURVALUMAB
ASTRAZENECA PHARMA - PERMISSION PAVES WAY FOR MARKETING OF DURVALUMAB SOLUTION IN INDIA
Source text: ID:nBSE4kw3HB
Further company coverage: ASTR.NS
(([email protected];))
Feb 10 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA PHARMA INDIA LTD - RECEIVES PERMISSION TO IMPORT DURVALUMAB
ASTRAZENECA PHARMA - PERMISSION PAVES WAY FOR MARKETING OF DURVALUMAB SOLUTION IN INDIA
Source text: ID:nBSE4kw3HB
Further company coverage: ASTR.NS
(([email protected];))
Sept 12 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA PHARMA INDIA - GETS SHOW CAUSE NOTICE FROM NATIONAL PHARMACEUTICAL PRICING AUTHORITY
ASTRAZENECA PHARMA INDIA LTD - NPPA ALLEGES OVERCHARGING FOR 'SYMBICORT TURBUHALER'
ASTRAZENECA PHARMA INDIA LTD - CLAIM QUANTUM 605 MILLION RUPEES
Source text: ID:nNSEb5xzyw
Further company coverage: ASTR.NS
(([email protected];))
Sept 12 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA PHARMA INDIA - GETS SHOW CAUSE NOTICE FROM NATIONAL PHARMACEUTICAL PRICING AUTHORITY
ASTRAZENECA PHARMA INDIA LTD - NPPA ALLEGES OVERCHARGING FOR 'SYMBICORT TURBUHALER'
ASTRAZENECA PHARMA INDIA LTD - CLAIM QUANTUM 605 MILLION RUPEES
Source text: ID:nNSEb5xzyw
Further company coverage: ASTR.NS
(([email protected];))
Sept 2 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
SURRENDERS MANUFACTURING LICENSE
Source text: ID:nBSE3qVVyp
Further company coverage: ASTR.NS
(([email protected];))
Sept 2 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
SURRENDERS MANUFACTURING LICENSE
Source text: ID:nBSE3qVVyp
Further company coverage: ASTR.NS
(([email protected];))
Corrects bullet 3 to say year-ago loss of 118 million rupees, not 188 million rupees; adds dropped word "rupees"
** Shares of AstraZeneca Pharma India ASTR.NS jump as much as 4.8% to 8,825 rupees
** Stock marks biggest intraday pct gain since June 2
** Biopharmaceutical co posts profit of 558.3 million rupees ($6.37 million) in June quarter, compared to a loss of about 118 million rupees a year ago
** More than 53,148 shares change hands, 2x of 30-day avg
** Stock up 20% YTD
($1 = 87.6230 Indian rupees)
(Reporting by Rudra Pratap Singh in Bengaluru)
Corrects bullet 3 to say year-ago loss of 118 million rupees, not 188 million rupees; adds dropped word "rupees"
** Shares of AstraZeneca Pharma India ASTR.NS jump as much as 4.8% to 8,825 rupees
** Stock marks biggest intraday pct gain since June 2
** Biopharmaceutical co posts profit of 558.3 million rupees ($6.37 million) in June quarter, compared to a loss of about 118 million rupees a year ago
** More than 53,148 shares change hands, 2x of 30-day avg
** Stock up 20% YTD
($1 = 87.6230 Indian rupees)
(Reporting by Rudra Pratap Singh in Bengaluru)
June 26 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA: EXPANDS BANGALORE GLOBAL HUB IN INDIA WITH 1.66 BILLION RUPEES INVESTMENT
Further company coverage: ASTR.NS
(([email protected];))
June 26 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA: EXPANDS BANGALORE GLOBAL HUB IN INDIA WITH 1.66 BILLION RUPEES INVESTMENT
Further company coverage: ASTR.NS
(([email protected];))
June 9 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA PHARMA INDIA LTD - SANJEEV KUMAR PANCHAL HAS OFFERED TO RESIGN AS MD
Source text: [ID:]
Further company coverage: ASTR.NS
(([email protected];))
June 9 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA PHARMA INDIA LTD - SANJEEV KUMAR PANCHAL HAS OFFERED TO RESIGN AS MD
Source text: [ID:]
Further company coverage: ASTR.NS
(([email protected];))
** AstraZeneca Pharma India ASTR.NS shares up 11.5% at 8,885 rupees, marking their biggest pct jump so far this year
** ASTR on Friday reported 48% surge in Q4 profit on strong performance of oncology and biopharma divisions
** AstraZeneca shares up 21.6% YTD vs 8.8% fall in Nifty pharma index .NIPHARM
(Reporting by Sethuraman NR in Bengaluru)
(([email protected]; (+91 9945291420); Reuters Messaging: [email protected] ))
** AstraZeneca Pharma India ASTR.NS shares up 11.5% at 8,885 rupees, marking their biggest pct jump so far this year
** ASTR on Friday reported 48% surge in Q4 profit on strong performance of oncology and biopharma divisions
** AstraZeneca shares up 21.6% YTD vs 8.8% fall in Nifty pharma index .NIPHARM
(Reporting by Sethuraman NR in Bengaluru)
(([email protected]; (+91 9945291420); Reuters Messaging: [email protected] ))
May 29 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
RECEIVES PERMISSION TO IMPORT OSIMERTINIB TABLETS
Source text: ID:nNSE5r4vcG
Further company coverage: ASTR.NS
(([email protected];;))
May 29 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
RECEIVES PERMISSION TO IMPORT OSIMERTINIB TABLETS
Source text: ID:nNSE5r4vcG
Further company coverage: ASTR.NS
(([email protected];;))
May 8 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
RECEIVES APPROVAL FOR ENHERTU IN INDIA
Source text: ID:nNSEXz4FK
Further company coverage: ASTR.NS
(([email protected];;))
May 8 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
RECEIVES APPROVAL FOR ENHERTU IN INDIA
Source text: ID:nNSEXz4FK
Further company coverage: ASTR.NS
(([email protected];;))
April 15 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
SURRENDERS MARKETING AUTHORISATION FOR OLAPARIB TABLETS
DISCONTINUATION DUE TO COMMERCIAL REASONS, NOT EFFICACY OR SAFETY
HOLDS ALL OTHER PERMISSIONS FOR OLAPARIB IN INDIA
NEVER MARKETED OLAPARIB INDICATION IN INDIA
Source text: ID:nBSE1YlFfg
Further company coverage: ASTR.NS
(([email protected];;))
April 15 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
SURRENDERS MARKETING AUTHORISATION FOR OLAPARIB TABLETS
DISCONTINUATION DUE TO COMMERCIAL REASONS, NOT EFFICACY OR SAFETY
HOLDS ALL OTHER PERMISSIONS FOR OLAPARIB IN INDIA
NEVER MARKETED OLAPARIB INDICATION IN INDIA
Source text: ID:nBSE1YlFfg
Further company coverage: ASTR.NS
(([email protected];;))
March 28 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
DISCONTINUING MANUFACTURING, MARKETING OF PROLONGED RELEASE ISOSORBIDE-5-MONONITRATE TABLETS BP
Source text: [ID:]
Further company coverage: ASTR.NS
(([email protected];))
March 28 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
DISCONTINUING MANUFACTURING, MARKETING OF PROLONGED RELEASE ISOSORBIDE-5-MONONITRATE TABLETS BP
Source text: [ID:]
Further company coverage: ASTR.NS
(([email protected];))
** AstraZeneca Pharma India ASTR.NS rises 2.1% to 7,622.9 rupees, highest in about a month
** Biopharmaceutical co receives Indian drug regulator's permission to import Durvalumab solution for sale, distribution
** Drug is used to treat patients with a certain type of lung cancer
** Shares trading above 50-, 100-, 200-day moving avg
** ASTR up 2.2% YTD, after gaining 32% in 2024
(Reporting by Aleef Jahan in Bengaluru)
** AstraZeneca Pharma India ASTR.NS rises 2.1% to 7,622.9 rupees, highest in about a month
** Biopharmaceutical co receives Indian drug regulator's permission to import Durvalumab solution for sale, distribution
** Drug is used to treat patients with a certain type of lung cancer
** Shares trading above 50-, 100-, 200-day moving avg
** ASTR up 2.2% YTD, after gaining 32% in 2024
(Reporting by Aleef Jahan in Bengaluru)
March 7 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
RECEIVES PERMISSION TO IMPORT DURVALUMAB SOLUTION
PERMISSION PAVES WAY FOR MARKETING DURVALUMAB SOLUTION IN INDIA
Source text: ID:nNSEb26vVv
Further company coverage: ASTR.NS
(([email protected];;))
March 7 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
RECEIVES PERMISSION TO IMPORT DURVALUMAB SOLUTION
PERMISSION PAVES WAY FOR MARKETING DURVALUMAB SOLUTION IN INDIA
Source text: ID:nNSEb26vVv
Further company coverage: ASTR.NS
(([email protected];;))
March 6 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
RECEIVES PERMISSION TO IMPORT PHARMACEUTICAL FORMULATIONS OF LOKELMA
Source text: ID:nNSE5FXNVQ
Further company coverage: ASTR.NS
(([email protected];;))
March 6 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
RECEIVES PERMISSION TO IMPORT PHARMACEUTICAL FORMULATIONS OF LOKELMA
Source text: ID:nNSE5FXNVQ
Further company coverage: ASTR.NS
(([email protected];;))
** AstraZeneca Pharma ASTR.NS rises 2.7% to 6,872.1 rupees; stock's biggest one-day gain since Feb. 3
** Biopharmaceutical co receives Indian drug regulator's permission to import Durvalumab solution for sale, distribution
** Drug is used to treat patients with a certain type of liver cancer
** Shares mark second-busiest session in about 2 weeks, with more than 11,000 shares traded
** Stock down 8% so far this year, after a 32% gain from 2024
(Reporting by Aleef Jahan in Bengaluru)
** AstraZeneca Pharma ASTR.NS rises 2.7% to 6,872.1 rupees; stock's biggest one-day gain since Feb. 3
** Biopharmaceutical co receives Indian drug regulator's permission to import Durvalumab solution for sale, distribution
** Drug is used to treat patients with a certain type of liver cancer
** Shares mark second-busiest session in about 2 weeks, with more than 11,000 shares traded
** Stock down 8% so far this year, after a 32% gain from 2024
(Reporting by Aleef Jahan in Bengaluru)
Feb 28 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
RECEIVES PERMISSION TO IMPORT DURVALUMAB FOR ADDITIONAL INDICATION
GETS PERMISSION FROM CENTRAL DRUGS STANDARD CONTROL ORGANISATION, INDIA
Source text: ID:nNSE3QqT8W
Further company coverage: ASTR.NS
(([email protected];;))
Feb 28 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
RECEIVES PERMISSION TO IMPORT DURVALUMAB FOR ADDITIONAL INDICATION
GETS PERMISSION FROM CENTRAL DRUGS STANDARD CONTROL ORGANISATION, INDIA
Source text: ID:nNSE3QqT8W
Further company coverage: ASTR.NS
(([email protected];;))
** Astrazeneca Pharma India ASTR.NS rises 2% to 7,609 rupees
** Q3 profit before exceptional item and tax jumps ~3.7x y/y, helped by strong demand for its oncology products; rev up 44%
** Co incurred one-off 335.5 million rupees ($3.9 mln) employee separation cost in the quarter
** More than 41,000 shares traded, 1.5x the 30-day avg
** Stock rose 32% in 2024
($1 = 86.8200 Indian rupees)
(Reporting by Aleef Jahan in Bengaluru)
** Astrazeneca Pharma India ASTR.NS rises 2% to 7,609 rupees
** Q3 profit before exceptional item and tax jumps ~3.7x y/y, helped by strong demand for its oncology products; rev up 44%
** Co incurred one-off 335.5 million rupees ($3.9 mln) employee separation cost in the quarter
** More than 41,000 shares traded, 1.5x the 30-day avg
** Stock rose 32% in 2024
($1 = 86.8200 Indian rupees)
(Reporting by Aleef Jahan in Bengaluru)
BENGALURU, Feb 11 (Reuters) - Diary of India economic, corporate events on Feb 11
ECONOMIC, CORPORATE .BSE500 EVENTS:
Key Speaker | Local Time | Location |
India Commerce Minister | 0935 | India Israel Business Forum, New Delhi |
Start Date | Start Time | RIC | Company Name | Event Name |
11-Feb-2025 | NTS | ASTR.NS | Astrazeneca Pharma India Ltd | Q3 2025 Astrazeneca Pharma India Ltd Earnings Release |
11-Feb-2025 | NTS | BAYE.NS | Bayer Cropscience Ltd | Q3 2025 Bayer Cropscience Ltd Earnings Release |
11-Feb-2025 | NTS | BRGR.NS | Berger Paints India Ltd | Q3 2025 Berger Paints India Ltd Earnings Release |
11-Feb-2025 | NTS | BIRS.NS | Birlasoft Ltd | Q3 2025 Birlasoft Ltd Earnings Release |
11-Feb-2025 | NTS | BLSN.NS | Bls International Services Ltd | Q3 2025 Bls International Services Ltd Earnings Release |
11-Feb-2025 | NTS | CAMU.NS | Campus Activewear Ltd | Q3 2025 Campus Activewear Ltd Earnings Release |
11-Feb-2025 | NTS | CERA.NS | Cera Sanitaryware Ltd | Q3 2025 Cera Sanitaryware Ltd Earnings Release |
11-Feb-2025 | NTS | DEVY.NS | Devyani International Ltd | Q3 2025 Devyani International Ltd Earnings Release |
11-Feb-2025 | NTS | EIDP.NS | E I D-Parry (India) Ltd | Q3 2025 E I D-Parry (India) Ltd Earnings Release |
11-Feb-2025 | NTS | EIHO.NS | EIH Ltd | Q3 2025 EIH Ltd Earnings Release |
11-Feb-2025 | NTS | HEGL.NS | HEG Ltd | Q3 2025 HEG Ltd Earnings Release |
11-Feb-2025 | NTS | INIR.NS | Indian Railway Catering and Tourism Corporation Ltd | Q3 2025 Indian Railway Catering and Tourism Corporation Ltd Earnings Release |
11-Feb-2025 | NTS | IRCN.NS | Ircon International Ltd | Q3 2025 Ircon International Ltd Earnings Release |
11-Feb-2025 | NTS | KIRO.NS | Kirloskar Oil Engines Ltd | Q3 2025 Kirloskar Oil Engines Ltd Earnings Release |
11-Feb-2025 | NTS | LUPN.NS | Lupin Ltd | Q3 2025 Lupin Ltd Earnings Release |
11-Feb-2025 | NTS | NBCC.NS | NBCC (India) Ltd | Q3 2025 NBCC (India) Ltd Earnings Release |
11-Feb-2025 | NTS | PROC.NS | Procter & Gamble Hygiene and Health Care Ltd | Q3 2025 Procter & Gamble Hygiene and Health Care Ltd Earnings Release |
11-Feb-2025 | NTS | RHIM.NS | RHI Magnesita India Ltd | Q3 2025 RHI Magnesita India Ltd Earnings Release |
11-Feb-2025 | NTS | SMMN.NS | Sammaan Capital Ltd | Q3 2025 Sammaan Capital Ltd Earnings Release |
11-Feb-2025 | NTS | SEIN.NS | Schneider Electric Infrastructure Ltd | Q3 2025 Schneider Electric Infrastructure Ltd Earnings Release |
11-Feb-2025 | NTS | TINV.NS | Tata Investment Corporation Ltd | Q3 2025 Tata Investment Corporation Ltd Earnings Release |
11-Feb-2025 | NTS | TEEC.NS | Techno Electric & Engineering Company Ltd | Q3 2025 Techno Electric & Engineering Company Ltd Earnings Release |
NTS - 'No time scheduled'
(Compiled by Bengaluru Newsroom)
BENGALURU, Feb 11 (Reuters) - Diary of India economic, corporate events on Feb 11
ECONOMIC, CORPORATE .BSE500 EVENTS:
Key Speaker | Local Time | Location |
India Commerce Minister | 0935 | India Israel Business Forum, New Delhi |
Start Date | Start Time | RIC | Company Name | Event Name |
11-Feb-2025 | NTS | ASTR.NS | Astrazeneca Pharma India Ltd | Q3 2025 Astrazeneca Pharma India Ltd Earnings Release |
11-Feb-2025 | NTS | BAYE.NS | Bayer Cropscience Ltd | Q3 2025 Bayer Cropscience Ltd Earnings Release |
11-Feb-2025 | NTS | BRGR.NS | Berger Paints India Ltd | Q3 2025 Berger Paints India Ltd Earnings Release |
11-Feb-2025 | NTS | BIRS.NS | Birlasoft Ltd | Q3 2025 Birlasoft Ltd Earnings Release |
11-Feb-2025 | NTS | BLSN.NS | Bls International Services Ltd | Q3 2025 Bls International Services Ltd Earnings Release |
11-Feb-2025 | NTS | CAMU.NS | Campus Activewear Ltd | Q3 2025 Campus Activewear Ltd Earnings Release |
11-Feb-2025 | NTS | CERA.NS | Cera Sanitaryware Ltd | Q3 2025 Cera Sanitaryware Ltd Earnings Release |
11-Feb-2025 | NTS | DEVY.NS | Devyani International Ltd | Q3 2025 Devyani International Ltd Earnings Release |
11-Feb-2025 | NTS | EIDP.NS | E I D-Parry (India) Ltd | Q3 2025 E I D-Parry (India) Ltd Earnings Release |
11-Feb-2025 | NTS | EIHO.NS | EIH Ltd | Q3 2025 EIH Ltd Earnings Release |
11-Feb-2025 | NTS | HEGL.NS | HEG Ltd | Q3 2025 HEG Ltd Earnings Release |
11-Feb-2025 | NTS | INIR.NS | Indian Railway Catering and Tourism Corporation Ltd | Q3 2025 Indian Railway Catering and Tourism Corporation Ltd Earnings Release |
11-Feb-2025 | NTS | IRCN.NS | Ircon International Ltd | Q3 2025 Ircon International Ltd Earnings Release |
11-Feb-2025 | NTS | KIRO.NS | Kirloskar Oil Engines Ltd | Q3 2025 Kirloskar Oil Engines Ltd Earnings Release |
11-Feb-2025 | NTS | LUPN.NS | Lupin Ltd | Q3 2025 Lupin Ltd Earnings Release |
11-Feb-2025 | NTS | NBCC.NS | NBCC (India) Ltd | Q3 2025 NBCC (India) Ltd Earnings Release |
11-Feb-2025 | NTS | PROC.NS | Procter & Gamble Hygiene and Health Care Ltd | Q3 2025 Procter & Gamble Hygiene and Health Care Ltd Earnings Release |
11-Feb-2025 | NTS | RHIM.NS | RHI Magnesita India Ltd | Q3 2025 RHI Magnesita India Ltd Earnings Release |
11-Feb-2025 | NTS | SMMN.NS | Sammaan Capital Ltd | Q3 2025 Sammaan Capital Ltd Earnings Release |
11-Feb-2025 | NTS | SEIN.NS | Schneider Electric Infrastructure Ltd | Q3 2025 Schneider Electric Infrastructure Ltd Earnings Release |
11-Feb-2025 | NTS | TINV.NS | Tata Investment Corporation Ltd | Q3 2025 Tata Investment Corporation Ltd Earnings Release |
11-Feb-2025 | NTS | TEEC.NS | Techno Electric & Engineering Company Ltd | Q3 2025 Techno Electric & Engineering Company Ltd Earnings Release |
NTS - 'No time scheduled'
(Compiled by Bengaluru Newsroom)
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Astrazeneca Pharma do?
AstraZeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. The company engages in execution of clinical studies to generate high quality data eligible for submissions to regulatory agencies across the world aimed at developing life altering medical products.
Who are the competitors of Astrazeneca Pharma?
Astrazeneca Pharma major competitors are Jubilant Pharmova, Alembic Pharma, Pfizer, Eris Lifesciences, Marksans Pharma, Natco Pharma, Caplin Point Labs.. Market Cap of Astrazeneca Pharma is ₹16,963 Crs. While the median market cap of its peers are ₹16,328 Crs.
Is Astrazeneca Pharma financially stable compared to its competitors?
Astrazeneca Pharma seems to be less financially stable compared to its competitors. Altman Z score of Astrazeneca Pharma is 8.93 and is ranked 4 out of its 8 competitors.
Does Astrazeneca Pharma pay decent dividends?
The company seems to pay a good stable dividend. Astrazeneca Pharma latest dividend payout ratio is 47.99% and 3yr average dividend payout ratio is 51.42%
How has Astrazeneca Pharma allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Astrazeneca Pharma balance sheet?
Balance sheet of Astrazeneca Pharma is strong. But short term working capital might become an issue for this company.
Is the profitablity of Astrazeneca Pharma improving?
The profit is oscillating. The profit of Astrazeneca Pharma is ₹170 Crs for TTM, ₹188 Crs for Mar 2026 and ₹116 Crs for Mar 2025.
Is the debt of Astrazeneca Pharma increasing or decreasing?
Yes, The net debt of Astrazeneca Pharma is increasing. Latest net debt of Astrazeneca Pharma is -₹884.26 Crs as of Mar-26. This is greater than Mar-25 when it was -₹1,073.4 Crs.
Is Astrazeneca Pharma stock expensive?
Astrazeneca Pharma is not expensive. Latest PE of Astrazeneca Pharma is 100, while 3 year average PE is 122. Also latest EV/EBITDA of Astrazeneca Pharma is 71.85 while 3yr average is 74.15.
Has the share price of Astrazeneca Pharma grown faster than its competition?
Astrazeneca Pharma has given better returns compared to its competitors. Astrazeneca Pharma has grown at ~24.04% over the last 9yrs while peers have grown at a median rate of 9.63%
Is the promoter bullish about Astrazeneca Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Astrazeneca Pharma is 75.0% and last quarter promoter holding is 75.0%.
Are mutual funds buying/selling Astrazeneca Pharma?
The mutual fund holding of Astrazeneca Pharma is increasing. The current mutual fund holding in Astrazeneca Pharma is 6.01% while previous quarter holding is 5.66%.